The DOI matches its Crossref record.
Adalimumab drug and antibody levels as predictors of clinical and laboratory response in patients with Crohn's disease
Abstract
Summary: Background: Adalimumab is an effective treatment for Crohn's disease (CD). Anti‐adalimumab antibodies (AAA) and low trough serum drug concentrations have been implicated as pre‐disposing factors for treatment failure. Aims: To assess adalimumab and AAA serum levels, and to examine their association and discriminatory ability with clinical response and serum C‐reactive protein (CRP). Methods: We performed a cross‐sectional study using trough sera from adalimumab‐treated CD patients. Demographical data, Montreal classification, treatment regimen and clinical status were recorded. Serum adalimumab, AAA and CRP were measured. Receiver operating characteristic analysis and a multivariate regression model were performed to find drug and antibody thresholds for predicting disease activity at time of serum sampling. Results: One hundred and eighteen trough serum samples were included from 71 patients. High adalimumab trough serum concentration was associated with disease remission (Area Under Curve 0.748, P < 0.001). A cut‐off drug level of 5.85 μg/mL yielded optimal sensitivity, specificity and positive likelihood ratio for remission prediction (68%, 70.6% and 2.3, respectively). AAA were inversely related with adalimumab drug levels (Spearman's r = −0.411, P < 0.001) and when subdivided into categorical values, positively related with disease activity (P < 0.001). High drug levels and stricturing vs. penetrating or inflammatory phenotype, but not AAA levels, independently predicted disease remission in a multivariate logistic regression model. Conclusions: Adalimumab drug levels were inversely related to disease activity. High levels of anti‐adalimumab antibodies were positively associated with disease activity, but this association was mediated mostly by adalimumab drug levels.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Loss of Response to Anti-TNFs: Definition, Epidemiology, and Management
Roda, G., Jharap, B., Neeraj, N., & Colombel, J.-F. (2016) · Clinical and Translational Gastroenterology · doi:10.1038/ctg.2015.63 · Cited by 723
Feuerstein, J. D., Nguyen, G. C., Kupfer, S. S., Falck-Ytter, Y., Singh, S., Gerson, L., Hirano, I., Nguyen, G. C., Rubenstein, J. H., Smalley, W. E., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.032 · Cited by 576
Turner, D., Ruemmele, F. M., Orlanski‐Meyer, E., Griffiths, A. M., de Carpi, J. M., Bronsky, J., Veres, G., Aloi, M., Strisciuglio, C., Braegger, C. P., et al. (2018) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/mpg.0000000000002035 · Cited by 481
Ungar, B., Levy, I., Yavne, Y., Yavzori, M., Picard, O., Fudim, E., Loebstein, R., Chowers, Y., Eliakim, R., Kopylov, U., et al. (2016) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2015.10.025 · Cited by 370
Self-citationDing, N. S., Hart, A., & De Cruz, P. (2016) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13445 · Cited by 309
Management Strategies to Improve Outcomes of Patients With Inflammatory Bowel Diseases
Colombel, J.-F., Narula, N., & Peyrin-Biroulet, L. (2017) · Gastroenterology · doi:10.1053/j.gastro.2016.09.046 · Cited by 299
Vande Casteele, N., Herfarth, H., Katz, J., Falck-Ytter, Y., & Singh, S. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.07.031 · Cited by 295
Mitrev, N., Vande Casteele, N., Seow, C. H., Andrews, J. M., Connor, S. J., Moore, G. T., Barclay, M., Begun, J., Bryant, R., Chan, W., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14368 · Cited by 282
Roblin, X., Marotte, H., Rinaudo, M., Del Tedesco, E., Moreau, A., Phelip, J. M., Genin, C., Peyrin–Biroulet, L., & Paul, S. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.07.010 · Cited by 279
Ungar, B., Kopylov, U., Engel, T., Yavzori, M., Fudim, E., Picard, O., Lang, A., Williet, N., Paul, S., Chowers, Y., et al. (2017) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.13862 · Cited by 118
Self-citation
Metadata
- Authors
- Mazor, Y., Almog, R., Kopylov, U., Ben Hur, D., Blatt, A., Dahan, A., Waterman, M., Ben‐Horin, S., & Chowers, Y.
- Venue
- Alimentary Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2014-07-15
- Volume
- 40
- Issue
- 6
- Pages
- 620-628
- ISSN
- 0269-2813 (ISSN-L)
- 1365-2036
- OpenAlex
- W2115112939
- Cited by
- 189
- References
- 0
- FWCI
- 13.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.